immune system

Top 10 Multiple Sclerosis Stories of 2019

Throughout 2019, Multiple Sclerosis News Today brought you daily coverage of the latest scientific findings, treatment developments, and clinical trialsĀ related toĀ multiple sclerosis (MS). We look forward to reporting more news to patients, family members, and caregivers dealing with MS during 2020. Here are the top 10 most-read articles of…

Long-term IFN-Beta Treatment Normalizes Immune Balance in RRMS, Study Shows

Long-term treatment with interferon beta (IFN-beta) corrects the defective immune balance characteristic of people withĀ relapsing-remitting multiple sclerosisĀ (RRMS), a study has found. The study also identified more than 200 genes with significantly different activity between complete and partial responders to IFN-beta treatment, which could be used to identify which…

Immune System Activation Induced by Filgrastim Likely Beneficial for Patients with Tysabri-associated PML, Study Says

Immune system activation induced by filgrastim may be beneficial for patients with progressive multifocal leukoencephalopathy associated with the use of Tysabri (natalizumab), without worsening multiple sclerosis (MS) progression, a study says. The study with that finding, “Treatment of natalizumabā€associated PML with filgrastim,” was published in…

A Fall, a Scratch, and an MS Lesson Learned

In mid-July, the woman who writes the Multiple ExperienceS blog had a little fall. As Jamie explains, her rollator went forward, but her feet didn’t. The fall left a small cut on her knee. Over the next few days, Jamie’s knee swelled, and a trip to her doctor,…

My Lemtrada Journey: A Little Dip on the Roller Coaster

I’m now three months past my second round of Lemtrada treatments, so it’s time for an update. I began Lemtrada (alemtuzumab) in December 2016, hoping it will be the last disease-modifying therapy that I’ll ever need to use. I’ve had peaks and valleys since this treatment began, thus…

Missouri Trial to Examine if Fasting Alters Gut Microbiome and Immune System of RRMS Patients in Helpful Ways

A 12-week clinical study is recruiting people with relapsing-remitting multiple sclerosis (RRMS) to evaluate if intermittent fasting can improve their immune response, metabolism, and gut microbiome ā€” the bacterial community that inhabits the gastrointestinal tract. Its findings may also hint at whether such a diet might ease MS symptoms or alter discourse course and, if used in conjunction with other treatments, boost their efficacy. Conducted by researchers atĀ Washington University in St. Louis, Missouri,Ā the trial is supported by their findings in an earlier mouse study.Ā  Results showed that fasting worked to ease MS-like symptoms in a mouse model of the disease, the research team reported. Specifically,Ā EAE mice fed every other day were less prone to symptoms that included difficulty in walking, limb weakness, and paralysis than mice allowed to eat freely.Ā  A fasting diet also enriched bacterial diversity in the mice guts, and shifted immune cell populations there toward a lower inflammatory response.Ā When gut bacteria were transferred from fasting mice to nonfasting mice, the later also were seen to be better protected against MS-like movement problems, supporting the influence of the gut microbiome on MS symptoms. Several diets have been proposed to help ease disease progression in MS patients, but solid scientific evidence is lacking to support any one diet over another, leaving the issue much to an individualā€™s choice. ā€œThe fact is that diet may indeed help with MS symptoms, but the studies havenā€™t been done,ā€ Laura Piccio, MD, an associate professor of neurology at WUSTL and the study's lead author, said in a WUSTL news releaseĀ written by Tamara Bhandari. Taking place at the Missouri university, the trialĀ is expected to enroll 60 RRMS patients.Ā Half will be randomly assigned to eat a standard Western-style diet seven days a week, and the other half to Western-style diet five days a week, with two days set aside for fasting (consuming a maximum of 500 calories each day). On fasting days, patients canĀ only drink water or calorie-free beverages and eat fresh, steamed or roasted non-starchy vegetables All will undergo a neurological assessment, and provide blood and stool samples in the study's beginning, at mid-point or week six, and at its end (week 12). Those using MS medications will continue on their prescribed treatment regimens throughout the study. More information, including enrollment information, is available here. Piccio noted thatĀ a pilot study on diet in 16 MS patients showed that limiting calories every other day for two weeks led to immune and gut microbiome changes that resembled those observed in the mice study she helped to lead. Its researchers concluded that intermittent fasting had the potential to positively manipulate the immune response in MS patients by changing their gut microbiome. The gut microbiome plays a central role in digestion, and in producing vitamins and amino acids (the building blocks of proteins). But a growing body of evidence indicates that it also determines how our immune systems develops and matures. Indeed, an increasing number of studiesĀ link irregularities in the gut microbiome with MS. ā€œThere are several possible ways fasting can affect inflammation and the immune response,ā€ Piccio said. ā€œOne is by changing hormone levels. We found that levels of the anti-inflammatory hormone corticosterone were nearly twice as high in the fasting mice. But it also could act through the gut microbiome.ā€ The new trial will allowĀ the team to analyze more deeply the effects of a fasting diet ā€” and perhaps gather evidence for a larger study investigating if skipping meals can ease MS symptoms. Its goal is to find out "whether people on limited fasts undergo changes to their metabolism, immune response and microbiome similar to what we see in the mouse,ā€ Piccio said. ā€œI donā€™t think any physician working with this disease thinks you can cure MS with diet alone,ā€ she added,Ā ā€œbut we may be able to use it as an add-on to current treatments to help people feel better.ā€

Overreactive T-cells Can Transition into T-cells That Control the Immune Response, Study Shows

New research shows that overreactive and tissue-damaging T-cells can transition into regulatory T-cells that help to control the immune system’s response. These findings open the door to further understanding of the mechanism underlying this transition, knowledge that can help scientists in designing more effective, targeted immunotherapies for diseases like multiple…

Symbiotix Obtains Access to Harvard Material That Could Help It Develop MS Therapies

Symbiotix BiotherapiesĀ has gained access to Harvard UniversityĀ material thatĀ could help it develop treatments for autoimmune and inflammatory diseases like multiple sclerosisĀ and inflammatory bowel diseases. It obtained access to the intellectual property, much of which deals with gut bacteria, under a licensing agreement with Harvard. Intellectual property typically includes…

Body’s Biological Clock and Time of Day Affects Immune Cells, Mouse Study Shows

Researchers further explored how our internal biological clock ā€” known as circadian rhythm ā€” influences immune system responses.Ā Disruptions to that rhythm are associated with immune diseases like multiple sclerosis (MS), although in waysĀ not fully understood and, the study suggests, may affect response to treatment. A natural 24-hour cycle that exists…

Human Vaccines Project Studies Aim to Unveil Workings of Immune System

Scientists announced positive and encouraging outcomes from two clinical studies ā€” running as part of the larger Human Vaccines ProjectĀ ā€” aiming to unravel the mechanisms that underlie our immune systemā€™s ability to fight disease. The results are expected to shed light on unknown aspects of the immune system that scientists at the Human Vaccines Project, a public-private partnership, hope to translate into new trials for diseases linked to the immune system, such as multiple sclerosis. Results from the trials ā€” the Human Immunome Program and the Immunity to Hepatitis B Vaccine study ā€” were recently presented at the World Vaccine and Immunotherapy Congress in San Diego, California. In the ongoing Human Immunome Program, researchers are trying to fill a major knowledge gap in the components and mechanisms of the immune system that allow it to recognize various threats, from viruses, parasites and bacteria to cancer cells. They are using blood samples from healthy people to analyze, at an unprecedented depth, the whole repertoire of genes that make up the surface receptors of immune B- and T-cells, the core cells of the immune systemā€™s defence mechanisms. Results will likely advance how scientists diagnose and treat various diseases, and could prompt the development of new, improved vaccines. "We are studying the immune systems of healthy individuals to identify common elements, which could be important for facilitating new and improved vaccines," James E. Crowe Jr., MD, director of Vanderbilt University Medical Center's Vaccine Center, the leading scientific institution of the Human Immunome Program, said in a press release. Researchers will cross the sequencing information with participants' microbiome composition ā€” the natural community of microbes that reside in an organism and are key for a healthy immune system ā€” and other health and sociodemographic characteristics. "We also plan to expand these studies to complete the catalog across different demographics and geographies and compare healthy subjects with individuals with immune-mediated diseases such as multiple sclerosis, cancer and Alzheimer's, which could also reveal novel diagnostic markers," Crowe said. The second study, the Immunity to Hepatitis B Vaccine trial ā€” currently recruiting participants ā€” aims to understand why some people achieve protection against Hepatitis B after a single vaccine shot, while others require up to three immunizations to acquire full immunity. Understanding why the immune system responds differently in individuals can help researchers improve existing vaccines and potentially lead to one-shot vaccines that provide long-term immunity for all populations. Researchers in this study are analyzing genes belonging to the innate-immune system ā€” a general immune system response, not one tailored to specific threats ā€” and observing that activation of these genes in certain immune cells can predict who will be a responder after a single shot of the Hepatitis B vaccine. Preliminary results of the Immunity to Hepatitis B Vaccine study were delivered in two separate sessions at the congress. One was given byĀ Manish Sadarangani, director of the Vaccine Evaluation Center of the University of British Columbia and BC Children's Hospital Research Institute, and the by and Richard Scheuermann, director of theĀ J. Craig Venter InstituteĀ in La Jolla, California. "These preliminary data points toward strategies to understand why some people respond better to vaccines than others," Sadarangani said. "Using single cell analyses, we now have the opportunity to probe vaccine-induced responses more effectively, to not only learn what happens immediately after vaccination, but to monitor responses over time and utilize machine learning to eventually predict the human immune response to vaccines," added Scheuermann. Wayne C. Koff, president and chief executive officer of the Human Vaccines Project, emphasized that researchers are optimistic with the results obtained so far, as they "provide important insights into the scale and complexity of the human immune system and how vaccines confer protective immunity." "With our network of academic and corporate partners, we aim to build on these findings and decode the human immune system, giving the world the tools required to advance the development of future vaccines and therapies to defeat major global diseases," Koff concluded. Ā